In hereditary neuropathies, next-generation sequencing techniques are producing a vast number of candidate gene mutations that need to be verified or excluded by careful genotype-phenotype correlation analysis. In most cases, clinical acumen is still important but needs to be combined with data from nerve conduction studies and, in some cases, from nerve biopsy examinations. Indeed, characteristic clinical, electrophysiological, and sometimes pathological features may be suggestive of a particular subtype of CharcotMarie-Tooth (CMT) disease. Microscopical (mainly ultrastructural) human nerve biopsy patterns may be related to CMT diseases and gene defects. Even today, it is important to recognize these characteristic lesions in the context of a chronic idiopathic neuropathy as they may help search for or reveal a sporadic form of CMT. In practice, these different types of lesions are often linked to the known function of the mutated genes. Only a few patients diagnosed or suspected as having a CMT disease need a nerve biopsy that can help find or confirm the causative gene mutation. The indication for this procedure should be based on a case-by-case discussion.
INTRODUCTION
Hereditary neuropathies comprise various disorders encompassing Charcot-Marie-Tooth disease (CMT), hereditary neuropathy with liability to pressure palsy (HNPP), hereditary motor neuropathy (HMN), hereditary sensory autonomic neuropathy (HSAN), as well as various other forms of inherited neuropathy such as familial amyloid polyneuropathy (FAP) (1) . CMT, or "hereditary motor and sensory neuropathy" (HMSN), is a heterogeneous group of inherited disorders sharing a characteristic clinical phenotype and a progressive course (2) . It represents the most common degenerative disorder of the peripheral nervous system (PNS), affecting up to 1 out of 1,214 individuals in some countries (3, 4) . This incurable disorder may be "demyelinating," "axonal," or "intermediate," based on electrophysiological and sometimes pathological criteria (5) . One century after the clinical description by Jean-Martin Charcot and Pierre Marie (France) (6) and Howard Tooth (Great Britain) (7) of the "peroneal muscular atrophy syndrome," the first genes were identified in patients with CMT (8, 9) . Since the 1990s, progress in molecular genetics and more recently the use of next-generation sequencing (NGS) have generated a vast number of candidate gene mutations that need to be verified or excluded by careful genotype-phenotype correlation analysis, which in turn complicates the current classification of CMT (1) . In most cases, clinical acumen is still essential, but needs to be combined with data from nerve conduction studies and, in some cases, from nerve biopsy findings. Characteristic clinical, electrophysiological, and sometimes pathological features may be suggestive of a particular subtype of CMT.
From our personal experience and study of the medical literature, our aim is to highlight data showing the usefulness of nerve biopsy studies in the clinical diagnosis of some hereditary neuropathies of any age, and also provide more evidence that a mutated gene detected by molecular biology is the cause of the neuropathy.
STEPS FOR DIAGNOSIS
The objective of the first part of the review is to discuss how to select patients who could benefit from a nerve biopsy in routine clinical practice. In most cases, clinical, electrophysiological, and family data are sufficient to diagnose the type of genetic neuropathy (mainly CMT) and sometimes to confirm a suspected mutated gene. Although there are reports of the value of a skin biopsy for detecting ultrastructural lesions, our experience is that biopsy of a sensory nerve (usually the sural nerve) is of more value. Examination of a skin biopsy can only detect tiny fascicules in the dermis, which even in normal individuals contain few myelinated and unmyelinated fibers. In most cases, the axons are not sufficiently orientated for reliable ultrastructural study. Fixation techniques are also different from those used for study of intraepidermic fibers for diagnosis of small fiber neuropathy. A single skin sample cannot therefore be used with the 2 different fixation techniques (10) .
All CMT variants share common symptoms and signs: motor weakness of lower extremities, foot deformities, sensory deficits (not always found), muscle atrophy, and absent deep tendon reflexes (2) . The first step is to perform nerve conduction studies in order to determine the electrophysiological type of the neuropathy. By evaluating motor and sensory nerves (and secondary muscle impairment), the electrophysiological examination is still a fundamental step in the diagnostic process of neuropathies, especially inherited ones. The reduction in amplitude of the compound muscle action potential and the sensory nerve action potential is correlated with the degree of axonal damage and loss of fibers. Conduction slowing provides indirect evidence of myelin dysfunction: it is usually considered a sign of demyelination (or hypomyelination), but nerve conduction velocity (NCV) reduction may also stem from other mechanisms (e.g. abnormalities of ion channels, nodo-paranodal abnormalities, and abnormalities of Schwann cell-axon interactions) (11) . A cut-off of 38 m/s for the median nerve motor NCV was proposed: value <38 m/s for demyelinating CMT and >38 m/s for axonal CMT; some authors also introduced the term "intermediate" for designating patients with electrophysiological features not fitting into either demyelinating or axonal (12) . Moreover, in CMT, NCV slowing is usually uniform and diffuse, whereas in the acquired inflammatory neuropathies (such as chronic inflammatory demyelinating polyradiculoneuropathy [CIDP]) it is nonhomogeneous, asymmetrical, and characterized by partial conduction blocks (conduction blocks are rare in CMT) (11, 13) .
The age of onset of the disease is also important: inherited neuropathies may have neonatal ("congenital neuropathies"), infantile, or late onset (1) . In familial cases, it is useful to determine the modalities of transmission: autosomal dominant, autosomal recessive, or X-linked. Autosomal recessive inheritance is less common, but should be considered in consanguineous families; autosomal dominant inheritance may also be observed in consanguineous families. In supposed sporadic forms, which are probably underestimated in adults, it is also important to look for characteristic clinical signs that could, if present, guide the genetic analysis and in turn the diagnosis of hereditary neuropathy. For example, optic atrophy (MFN2), renal failure (INF2), vocal cord paresis (TRPV4), and others, may suggest involvement of certain specific genes (Table) .
By taking these data into account, it is possible to direct guide the molecular studies. Murphy et al studied 916 patients and found that 4 common genes (PMP22, GJB1, MPZ, and MFN2) accounted for >90% of all CMT molecular diagnoses (14) , which has been confirmed by others (15) . So, in practice, most of the genetic laboratories systematically look for a PMP22 duplication (using the Sanger method). This will be discussed below under "lesions induced by anomalies of the PMP22 gene." If this most frequent gene anomaly is not found, clinical findings, hereditary transmission, and electrophysiological studies can orientate a search for a pathogenic variant in the 3 other most common genes (GJB1, MPZ, and MFN2). If these first tests are negative, with the rapid development of NGS, it is now possible to test all known CMT genes for several patients in a single test, although there may be problems with interpretation of the identified variants. The causative nature of a new sequence variant or the presence of several genetic variants in the same individual (oligogenic inheritance or rare "private" polymorphisms in >1 CMT genes) may not be straightforward. Nevertheless, in 2 separate recent studies (employing either a 56-or 70-gene CMT panel in patients negative for the common CMT mutations), diagnostic rates of only 12% and 27%, respectively, were found (16, 17) .
Thus, in some familial cases and even more so in sporadic cases, the clinical, electrophysiological, and molecular data may be unable to confirm that the patient has a genetic neuropathy or specify its subtype if the mutated gene is not identified. In such conditions, nerve biopsy can be helpful, its indication relying on a case-by-case discussion. By demonstrating the presence of characteristic pathological lesions (mainly by electron microscopy [EM]) of either axons, myelin, or nodes of Ranvier, nerve biopsy may point to particular mutations in some genes; these various microscopical lesions in nerve biopsies often being linked to the known function of the mutated genes (Table) . Nerve biopsy may also be helpful to orientate genetic testing in sporadic cases presenting as a chronic idiopathic neuropathy (especially in the absence of any evocative clinical/biological sign), in cases of several genes found by NGS and in floppy neonates (congenital neuropathy). Otherwise, distal atrophy, which characterizes CMT, may also be encountered in other rare familial neuropathies such as "giant axonal neuropathy" (GAN) and FAP. Our proposals for the selection of patients (with inherited neuropathy) who would benefit from a nerve biopsy are summarized in Figure 1 .
MICROSCOPIC LESIONS IN NERVE BIOPSIES OF GENETIC NEUROPATHIES OF CMT TYPE Nonspecific Lesions
These microscopical lesions may be encountered in any genetic neuropathy: some of them correlate with the electrophysiological data.
Axonal Loss
With time, any chronic polyneuropathy induces axonal loss which is variable in severity, but may be quite significant in this context. It is usually considered that axonal loss is responsible for disability in CMT patients. It may concern both myelinated and unmyelinated axons, and is usually homogeneous between fascicles. Some etiologies such as hereditary sensory autonomic neuropathy (HSAN) and FAP induce a more intense loss of nonmyelinated fibers that correlates with the severity of the autonomic clinical signs; nevertheless, in HSAN1 (due to SPTLC1 mutations), the reduction in unmyelinated fibers seems to be less severe than it is in other subtypes (18) .
In this context of genetic neuropathy, mainly in infant cases, the mechanism of the axonal rarefaction has to be discussed as it can also be secondary to an anomaly of development, and may correspond to the so-called entity "congenital axonal neuropathy."
Demyelination/Remyelination
Demyelination characterizes the CMT1 subtype (CMTde). It corresponds to the loss of myelin in 1 or several internodes (corresponding to the territory of 1 myelinating Schwann cell between 2 nodes of Ranvier where the process usually starts) and is often followed by remyelination: myelin sheaths being normally compacted but often too thin relative to axonal diameters. Quite often, they are surrounded by "onion-bulb" Schwann cell proliferations. With time, in chronic neuropathies, the demyelination/remyelinating process induces axon loss.
Inflammatory Signs
The presence of inflammatory infiltrates, composed by lymphocytes and macrophages, may be encountered in some cases (19) . Indeed, various CMT subtypes linked to different genes may be involved, for example, PMP22, MPZ, GJB1, and GDAP1 (and unpublished personal cases). The presence of inflammatory infiltrates does not indicate the involvement of specific genes. Such infiltrates may lead to misdiagnosis, with some cases of hereditary neuropathies being initially considered and treated as CIDP (20) . Various hypothesis have been suggested to explain the presence inflammatory infiltrates in hereditary neuropathies, such as a greater susceptibility to inflammation (B cells) in CMT1A (21) , involvement of immune cells (macrophages and T lymphocytes) in primary genetically mediated demyelination (22) , or the superimposition of a proven CIDP on a hereditary neuropathy.
Characteristic Lesions in PMP22-Related Neuropathies
Nerve biopsy may facilitate a diagnosis of atypical and sporadic forms of PMP22-related neuropathies in cases of "idiopathic" nonfamilial chronic neuropathies (sporadic cases). Although there are no specific lesions, several are evocative.
The PMP22 gene was the first identified in the 1990s (8, 9, 23) . PMP22 is a small-sized membrane protein (22 kDa), one of the components of compact myelin of the PNS. In adulthood, although it is highly expressed in Schwann cells (where it accounts for 2%-5% of the compact myelin), its function has not been fully elucidated; it probably plays a crucial role in the functions of the neurons expressing it in the early stages of embryonic development, and it may be required for mesaxon formation, as suggested through observations on mice lacking PMP22 (24, 25) . Duplication of the PMP22 gene is associated with the classical clinical form of CMT (and the most frequent one) called CMT1A (or AD-CMTde-PMP22dup). Ultrastructurally, it is characterized by the presence of many "onion bulb" formations (Fig. 2) , which suggests a chronic demyelination-remyelination process, inducing concentric proliferations of elongated cytoplasmic fragments (nucleated or not) of Schwann cells or of fragments of basal lamina that often appear too thin compared with the diameter of the axon that they surround. These lesions result in "hypertrophic neuropathies" (nerves appearing thick and palpable) that are not specific for CMT1A, and can be observed in Dejerine-Sottas syndrome, as well as in 10%-43% of chronic demyelinating acquired neuropathies such as CIDP (26) . However, in CMT1A, "onion bulb formations" are more diffuse; in CIDP, the interspaces of "onion bulbs" have been described as usually packed with collagen, whereas these interspaces seem to be void in patients with CMT1A. Additionally, onion bulbs are strongly immunoreactive for extracellular matrix protein such as Tenascin-C in CIDP nerve samples (27) , whereas immunoreactivity is rare in CMT1A. In CMT1A (as in CMT1B), demyelination seems stable over time whereas axonal loss evolves over years (28) .
The deletion of PMP22 induces autosomal dominant hereditary neuropathy with liability to pressures palsies (HNPP). This disorder is characterized by the presence of tomacula, which are multifocal hypermyelinating processes (Fig. 3) that appear longitudinally like a "chain of sausages." Their average diameter is 14.1 mm (63.5), and their average length is 77.4 mm (616.1) (29); a few CMT1A patients may also present such pathological lesions (30) . Pathological findings of CMT due to frame shift mutations of the PMP22 gene are similar to those observed in cases of PMP22 duplication, with severe rarefaction of myelinated fibers and profusion of "onion bulbs"; tomacula may be observed (31) . However, it is also possible to observe decreased thickness of myelin sheath without "onion bulbs" in cases with nonsense mutations; decompaction of the myelin sheath (with short intermodal areas) may also be observed (32) .
Characteristic Lesions in Non-PMP22-Related Neuropathies

Uncompacted Myelin Lamellae
Lack or loss of compaction of the layers of the myelin sheaths are evocative of myelin protein zero (MPZ) mutations (AD-CMTde-MPZ or CMT1B) (33) . MPZ codes for the P0 glycoprotein, mainly expressed in Schwann cells, and accounts for $50% of components of the myelin sheath of peripheral nerves. P0 is essential for the maintenance of the structure of the myelin sheath, especially at the level of the periodic lines. During the process of myelination, P0 may support the compaction of myelin by excluding myelin-associated glycoprotein (MAG) (34). Ohnishi et al distinguished regular widening between major dense lines due to a dissociation of the paired intraperiod lines, and moderately irregularly and markedly irregularly uncompacted myelin sheaths (35) . These lesions may involve the entire thickness of the myelin sheath or only part of it (Fig. 4) ; they have the same size in an individual patient, but vary between patients and they resemble those found in the P0 KO mouse model (36) . We reported 2 cases for whom the consanguinity and the demyelinating electrophysiological data pointed to a diagnosis of CMT4 (ARCMTde); however, the detection of abnormal and regular widening between the major dense lines of the myelin lamellae (by EM) enabled us to identify 2 P0 heterozygous mutations: S63F and N131Y (37) .
Other types of widened myelin lamellae are also observed in acquired neuropathies such as POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes) syndrome (38) , IgM monoclonal gammopathy with anti-MAG activity, and very rarely neuropathy associated with IgA or IgG monoclonal gammopathy (39) .
Foldings
Some axons may have unusually thick myelin wrappings and foldings (Fig. 5) , along with abnormal adhesion and compaction of myelin resulting from the P0 gene mutation. In a few CMT1B (AD-CMTde-MPZ) cases, these foldings involve most of the myelinated fibers. By EM, it is possible to describe infoldings that can distort the transverse profile of the axon and outfoldings that extend into the Schwann cell cytoplasm (28). These excessive foldings are different from typical tomaculae formations characterized by focal hypermyelination with smooth external contours.
Otherwise, most reported CMT patients with focally folded myelin sheaths have a rare autosomal recessive form and are classified as having CMT4B that are linked to mutations of MTMR2 (AR-CMTde-MTMR2) (Fig. 6) , MTMR12 (AR-CMTde-MTMR12), and MTMR5 (AR-CMTde-MTMR5) genes. Myotubularins (MTMR), members of the PTP (protein tyrosine phosphatase) family, are involved in membrane targeting, vesicle trafficking, and regulation of the transduction signal. Four myotubularins are known to be involved in the genesis of neuromuscular pathologies: MTMR1 (XL myotubular myopathy), MTMR13 (CMT4B2), MTMR14 (central core myopathy central-nuclear), and MTMR2 (CMT4B1); MTMR2 acts more particularly on the maturation of the endosomes (40) . Nerve biopsy of patients with MTMR2 (or MTMR13) mutations often showed severe axonal loss and "onion bulb" formations; however, the most characteristic element is the presence of many "outfoldings" and sometimes "infoldings" (41) . In a mouse model of CMT4B1, these outfoldings appeared between the third and fourth weeks of life, without axonal loss at the time: they are mainly located at paranodal areas, but also extend into internodal areas (42) .
FGD4 (Frabin)-related CMT (CMT4H) is a member of the guanine nucleotide exchange factor (GEF) family related to the Rho-GTPase Cdc42 that plays an important role in the maintenance of the actin cytoskeleton and microtubule network; investigations in animal models show that deficits in Cdc42 and FDG4 have similar consequences (43) . Nerve biopsy usually shows a severe loss of myelinated fibers, with some "onion bulb" formations and outfoldings similar to those of CMT4B (44) .
Tomacula
We mentioned previously that these quite characteristic lesions are mainly induced by a PMP22 deletion.
Extensions of the Cytoplasm of Schwann Cells
SH3TC2, a protein specifically expressed in Schwann cells, is controlled by the CREB (Camp-response elementbinding protein) transcription factors and SOX10 and plays a role in the process of myelination and maintenance of integrity of the nodes of Ranvier. SH3TC2 interacts in particular with Rab11, a small GTPase that helps recycle the internalized cellular membranes (and their membrane receivers). SH3TC2 also interacts with ERBB2 (elements involved in the process of myelination) by ensuring regulation of the intracellular traffic of ERBB2 (45) . Nerve biopsy of patients with SH3TC2-related neuropathy (CMT4C) shows demyelination with some "onion bulb" formations, which are mainly constituted by concentric proliferations of basal lamina (affecting both myelinated and unmyelinated fibers). The hallmark of SH3TC2-related neuropathy is the presence of abnormal extensions of the cytoplasm of Schwann cells (46) . AD-CMTin-INF2 (or "CMTDIE") is due to changes in the INF2 (inverted formin 2) gene, recognized as the cause a renal pathology called "autosomal dominant focal segmental glomerulosclerosis." The characteristic of CMTDIE is indeed the association of hereditary neuropathy and renal failure (47) . Microscopical lesions suggest chronic demyelination/remyelination and progressive axonal loss. By EM, there are unusual whorl-like proliferations of flattened Schwann cell cytoplasm and anomalies of unmyelinated Schwann cell cytoplasm, with supernumerary elongated extensions (like "filopodiae") similar to those described in CMT4C (SH3TC2). Abnormal accumulation of A-actin in the cytoplasm of Schwann cells has been found, suggesting a Schwann cells actinopathy (48); otherwise, other authors also described prominent axoplasmic reticulum profiles (49) and nodal widening (50) .
Disruption of Cajal Bands
CMT due to mutations of PRX (periaxin) was initially described in a Lebanese family (51) , and is currently referred to as CMT4F (AR-CMTde-PRX). PRX codes for S-periaxin and L-periaxin, 2 crucial proteins for the formation and maintenance of peripheral nerves. Cajal bands are cytoplasmic channels characterized by the abaxonal surface of the myelin sheath that apposes and adheres to the plasma membrane; these appositions contain a dystroglycan complex that includes periaxin and dystrophin-related protein 2. PRX mutations disrupt Cajal bands in Schwann cells and cause a severe demyelinating neuropathy in mice (52) . In 2 human nerve biopsies, we also observed anomalies of Cajal bands that we did not observe in any other neuropathy (Fig. 7) ; identical lesions have been reported in the dermal nerve fibers of 1 patient (53).
Paranodal Abnormalities
CNTNAP1 encodes the contactin-associated protein (Caspr-1), a cell adhesion protein involved in the proper formation of paranodal junctions, which are an essential component of both PNS and CNS. Caspr-1 interacts with contactin-1, a glycosyl-phosphatidyl-inositol-anchored neural cell adhesion molecule; contactin-1/caspr-1 complex, associated with NF155 (neurofascin-155), is located in the paranodal area. These proteins are essential components of the junctional attachment between axon and Schwann cell at the level of myelin loops (54) . CNTNAP1 mutations cause CNS hypomyelination and peripheral neuropathy, with or without arthrogryposis (55, 56) . They induce ultrastructural lesions of the paranodal region of peripheral nerves characterized by an absence of transverse bands resulting in a widening of the paranodal junctional gap between myelin loops and axolemma ( Fig. 8) (54) .
Adaxonal Deposits
Neuropathies related to mutations of NDRG1 (N-myc downstream-regulated gene1), called CMT4D (AR-CMTdDe-NDGR1), are usually reported in Gypsies (initially described in the town of Lom, Bulgaria) (57), although some cases without Gypsy ancestors have also been described. Nerve biopsy reveals a severe loss of myelinated fibers and persistence of several myelinated fibers with very thin myelin sheaths relative to the diameter of their axons (58) . Similar aspects were observed in mouse models, in a Greyhound dog (carrying a deletion of NDRG1) and in a Malamute dog (carrying the Gly98Val mutation of NDRG1) (59). Usually, "onion bulb" formations are numerous, but they decrease with the increase in axonal loss (58) . The pathological hallmark of the disease is the presence of pleomorphic granular deposits (sometimes with filaments or vesicles filled with glycogen) in the adaxonal space of myelinated fibers; however, this aspect, although characteristic of CMT4D, is not a systematic finding (58) . The role of NDRG1 within the Schwann cells remains unknown, but these deposits could derive from actin. A deficit in NDRG1 may involve metabolism of lipids and differentiation of myelinated cells (60) .
Mitochondrial Abnormalities
MFN2 (mitofusin 2) is a protein located in the outer membrane of mitochondria that plays important role in the process of mitochondrial fusion and in the links between the endoplasmic reticulum and mitochondria (by regulating the transfer of calcium from the endoplasmic reticulum toward mitochondria) (61) . AD-CMTax-MFN2 (CMT2A2) is characterized by prevalent axonal lesions, sometimes associated with "onion bulbs." By EM, the morphology of mitochondria is better studied on longitudinal sections in both myelinated and unmyelinated axons; in a normal nerve, mitochondria are elongated and randomly scattered. In this CMT subtype, mitochondria are aggregated, round and their crests are destroyed or irregularly arranged; some of them contain abnormal amorphous material (Fig. 9) . It is possible to observe these abnormal mitochondria along the axons of both myelinated and unmyelinated fibers, and more rarely in the cytoplasm of Schwann cells (62, 63) .
GDAP1 (ganglioside-induced differentiation-associated protein 1) appears to have a neuroprotective effect. It is located in the outer mitochondrial membrane, associated with the mitochondrial network (deleted "dynamics"); it may also be involved in energy production and in control of mitochondrial volume (64) . Pathologically, GDAP1-related neuropathies are characterized by a variable loss of large myelinated fibers and reduction in myelin thickness. "Onion bulb" formations may be observed, as well as occasional clusters of small regenerating fibers. We have studied, by EM (longitudinal sections), several cases and observed that mitochondria of myelinated and unmyelinated axons are smaller than normal (abnormally round) and that crests are often destroyed (Fig. 9, personal data) . These anomalies resemble those we observed in cases of MFN2 mutations.
Clusters of Regeneration
X-CMT-GJB1 (CMTX1) is the most frequent form of X-CMT. GJB1 (gap junction beta 1) codes for connexin 32 (Cx32), a protein present in noncompact myelin of the PNS at paranodal areas and Schmidt-Lantermann incisures, where it forms "gap junctions" (65) . Nerve biopsy usually shows marked reduction in the number of myelinated fibers and significant and unusual clusters of regeneration (many more than in other forms of CMT), composed of several closely packed unmyelinated and myelinated axons (each lined by a basement membrane). Finally, an overly thin myelin sheath may also be observed, as well as "onion bulbs" (but less frequently than demyelinating AD-CMT). By EM, it is sometimes possible to observe widenings of the adaxonal cytoplasm compartment of the Schwann cell and increased packing density of neurofilaments (66) .
Giant Axons
Giant axonal neuropathy (GAN) is a rare autosomal recessive childhood disorder characterized by peripheral neuropathy and features of CNS involvement. Nevertheless, some authors have shown that a few cases present with other clinical phenotypes (67). Zemmouri et al described 4 patients belonging to a consanguineous Algerian family with late onset (6-10 years), the propositus presenting with a CMT2-like phenotype with foot deformity and distal amyotrophy of lower limbs (68) . CNS involvement occurred several years later. Nerve biopsy showed moderate axonal loss with several giant axons filled with neurofilaments (Fig. 10) . A mutation of the GAN gene gigaxonin (encoding a protein implicated in cytoskeleton functions and dynamics) has been reported in this family later (family 6) (67). Otherwise, we described a consanguineous Algerian family with 3 affected siblings (aged 16, 14, and 12 years) who presented with mild chronic demyelinating sensorimotor neuropathy, hypoacousia, and kyphoscoliosis (which were moderate in the 2 older children and severe in the younger child), with no sign of CNS involvement and normal cerebral MRI (67) . This phenotype was in favor of a recessive, demyelinating motor, and sensory neuropathy. Surprisingly, nerve biopsy showed a moderate loss of myelinated fibers and a significant number of giant axons with thin or absent myelin, filled with neurofilaments. In fact, genetic study of this family demonstrated that this family was linked to the SH3TC2 gene (67) . Thus, in the presence of giant axons without mutations in the GAN gene, SH3TC2 and NEFL genes should be screened.
NEFL (neurofilament protein light polypeptide) encodes the light chains of neurofilaments (NF-L), a major component of the intermediate filaments (playing a main function in assembly and maintenance of the axon cytoskeleton). Such neuropathies were initially described as autosomal dominant axonal CMT (CMT2E), but some patients clearly have the electrophysiological pattern of autosomal dominant demyelinating neuropathy (CMT1F). Nerve biopsy usually shows significant rarefaction of myelinated fibers, numerous "onion bulb" formations, irregular aspect of the myelin sheaths (sometimes with "foldings"), and clusters of regeneration. Unmyelinated fibers may appear abnormally condensed, containing aggregates mixing with glycogen granules and the dense microtubules (69, 70) ; sometimes, giant axons are observed (70, 71) . In other contexts, it is recognized that identical giant axons dominate the pathologic picture of toxic neuropathies induced by iminodipropionitrile and 2,5-hexanedione (affecting the slow axonal transport of neurofilaments) (72) .
Severe Selective Rarefaction of Large Myelinated Fibers CMT2B1 (AR-CMTax-LMNA) is associated with mutations of LMNA (lamin A/C) that encodes for type A and type C lamins, structural proteins (intermediate filaments) of the nuclear envelope. "Laminopathies" include various pathologies such as neuromuscular disorders, cardiomyopathy, and others. This diversity of clinical phenotypes could be explained by the large variety of functions of lamin A/C, including maintenance of nuclear structure, regulation of transcription, and organization of heterochromatin (73) . Nerve biopsy shows significant loss of myelinated fibers, predominantly the large ones. Unmyelinated axons are not involved. There is no sign of demyelination-remyelination and no clusters of regeneration, which suggests that this degenerative process starts before birth (74) .
Amyloid Deposits
A few patients with genetic amyloid polyneuropathy may present with chronic distal sensory-motor neuropathy, and CMT is sometimes evoked on clinical considerations. If the case is sporadic, nerve biopsy may unexpectedly reveal amyloid deposits, mainly in cases of FAP induced by a de novo mutation of an amyloidogenic gene with onset at any age in adults.
Amyloid deposits are disseminated in various tissues, stained pink with hematoxylin and eosin, metachromatically with methyl violet or crystal violet and are specifically stained red with Congo red. In this context, the abnormal amyloid fibrils identified by EM are composed of a mutant transthyretin (TTR) protein (prealbumin), which is the result of a substitution of methionine for valine at position 30 of the transthyretin gene (TTR, Val30Met) (75) . A number of less frequent mutations in the TTR gene have been described, however, Val30Met remains the most common pathogenic point mutation that causes FAP worldwide. Other mutated genes such as gelsolin or apolipoprotein can induce FAP in rare cases (75) .
Nerve Biopsy in Congenital Neuropathy
Hypotonia in a neonate presents a diagnostic challenge for clinicians. The differential diagnosis for neonatal hypotonia is extensive: a methodical approach helps in localizing the problem (central nervous system disorder, PNS disorder, or muscular disorder) and formulating a differential diagnosis (76) . Although clinicians usually evoke anterior horn disease (Werdnig-Hoffmann syndrome) or myopathy, congenital neuropathy may be another cause of "floppy neonates." Such neuropathies correspond to various entities: "congenital hypomyelinating neuropathy," "congenital amyelinating neuropathy," or "congenital axonal neuropathy," and are usually characterized by severe hypotonia and weakness, appearing at birth or in infancy, with or without arthrogryposis, and resulting in a slow progression of motor development (sometimes with rapidly fatal outcome due to respiratory distress) (77) . These rare disorders may be due to mutations of many genes (e.g. MPZ, PMP22, EGR2, PRX, CNTNAP1, MFN2, GDAP1, MTMR2, MTMR13, SOX 10) and even duplication of the PMP22 gene (25) . Each of these mutated genes induce characteristic nerve lesions as described earlier. If the family history is not known, or if the case is considered to be sporadic, an ultrastructural study of a nerve biopsy may point to a diagnosis of genetic neuropathy and indicate the abnormal gene, which can help with genetic counseling. Congenital amyelination (i.e. total absence of myelin with normal axons in the PNS) has also been observed with EGR2 (77) and LMNA mutations (associated with muscular dystrophy) (78) (Fig. 11) .
Dejerine-Sottas disease (DSD) was first described in 1890 as a new entity different from CMT, but some authors considered it as a variant of CMT. In the 1970s, DSD was classified as hereditary motor and sensory neuropathy (HMSN) III (79, 80) ; now, it is often considered as a "hypertrophic CMT demyelinating subtype" (HMSN I or CMT1). DSD is characterized by nerve hypertrophy induced by proliferations of Schwann cells resembling "onion bulbs," which are more marked in HMSN III. DSD has progressively become synonymous for severe early-onset demyelinating CMT. It is also considered as a continuum between congenital hereditary neuropathy and demyelinating CMT. Because advances in molecular genetics have shown different mutations in a number of genes (e.g. PMP22 mutations and duplications, MPZ, GDAP1, EGR2, PRX, and MTMR2), DSD is now considered to be a syndrome rather than a disease.
Some other congenital neuropathies are associated with signs of CNS involvement with variable severity, including an absence of psychomotor development and premature death in the first weeks or months, and less severe forms that are characterized by the slow development of epilepsy, dementia, and death in some patients. Nevertheless, polyneuropathy may be the predominant symptom. Several disorders should be considered in the differential diagnosis such as inborn deficiencies of lysosome enzymes (neurolipidosis, leukodystrophies) leading to an abnormal lipid accumulation in cells. Thus, the nature of the stored material can be determined by nerve biopsy with ultrastructural examination. Microscopic nerve examination can be useful in the diagnosis of neuronal ceroidlipofuscinosis, mucopolysaccharidosis, neuroaxonal dystrophy, polyglucosan body disease, and others (81) . Currently, most of these diseases are diagnosed by molecular biology, which identifies specific mutated genes, and nerve biopsies are no longer used.
Conclusion
At a time when new techniques in molecular biology (e.g. NGS) identify a large number of candidate gene variants that may or may not be responsible for hereditary neuropathies, the genotype-phenotype correlation can be established or verified from the family history, clinical examination, and electrophysiological data. However, in some selected cases, nerve biopsy can help establish this correlation. In most cases, EM examination of a nerve sample is required to detect the characteristic and sometimes specific lesions induced by the mutated gene. Otherwise, in the context of a chronic sporadic idiopathic neuropathy, nerve biopsy may also help search for or reveal a sporadic form of CMT.
